鲁抗医药
(600789)
| 流通市值：90.95亿 | | | 总市值：90.95亿 |
| 流通股本：8.99亿 | | | 总股本：8.99亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,233,090,168.38 | 4,666,958,713.84 | 3,279,482,998.21 | 1,798,732,648.44 |
| 营业收入 | 6,233,090,168.38 | 4,666,958,713.84 | 3,279,482,998.21 | 1,798,732,648.44 |
| 二、营业总成本 | 5,966,978,980.46 | 4,545,910,874.37 | 3,176,523,878.63 | 1,738,362,575.97 |
| 营业成本 | 4,739,468,856.52 | 3,648,587,250.37 | 2,543,349,663.59 | 1,367,318,754.68 |
| 税金及附加 | 54,579,240.36 | 38,632,085.5 | 29,121,046.78 | 15,437,360.55 |
| 销售费用 | 568,066,831.42 | 422,545,887.95 | 307,817,727.36 | 201,910,852 |
| 管理费用 | 234,127,671.79 | 167,740,247.98 | 113,318,615.75 | 55,452,447.54 |
| 研发费用 | 317,146,873.44 | 223,166,241.03 | 158,893,369.08 | 80,658,203.12 |
| 财务费用 | 53,589,506.93 | 45,239,161.54 | 24,023,456.06 | 17,584,958.08 |
| 其中:利息费用 | 75,379,945.74 | 57,159,383.33 | 36,765,247.35 | 19,033,208.67 |
| 其中:利息收入 | 12,478,792.03 | 8,852,703.68 | 6,110,941.26 | 2,237,040.63 |
| 加:公允价值变动收益 | 29,520 | 46,740 | -152,520 | -71,340 |
| 加:投资收益 | -7,590,617.17 | -5,912,690.95 | -3,877,509.5 | -1,772,263.23 |
| 资产处置收益 | 153,424,695.55 | 155,939,515.06 | 155,939,515.06 | 63,705.4 |
| 资产减值损失(新) | -66,942,918.06 | 3,517,831.84 | -4,864,238.21 | 1,793,991.06 |
| 信用减值损失(新) | -13,700,137.89 | -10,276,477.51 | -13,955,785.13 | -7,079,311.49 |
| 其他收益 | 104,858,031.51 | 108,177,621 | 84,117,432.8 | 27,278,360.95 |
| 营业利润平衡项目 | 0 | 0 | 0.01 | 0 |
| 四、营业利润 | 436,189,761.86 | 372,540,378.91 | 320,166,014.61 | 80,583,215.16 |
| 加:营业外收入 | 1,683,481.16 | 962,910.82 | 780,095.21 | 347,557.05 |
| 减:营业外支出 | 3,971,830.51 | 1,175,178.09 | 30,639.29 | 11,641 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 433,901,412.51 | 372,328,111.64 | 320,915,470.53 | 80,919,131.21 |
| 减:所得税费用 | 25,553,890.68 | 15,408,896.23 | 14,204,768.43 | 9,952,425.09 |
| 六、净利润 | 408,347,521.83 | 356,919,215.41 | 306,710,702.1 | 70,966,706.12 |
| 持续经营净利润 | 408,347,521.83 | 356,919,215.41 | 306,710,702.1 | 70,966,706.12 |
| 归属于母公司股东的净利润 | 394,615,735.73 | 347,058,438.6 | 299,962,355.17 | 67,307,574.42 |
| 少数股东损益 | 13,731,786.1 | 9,860,776.81 | 6,748,346.93 | 3,659,131.7 |
| (一)基本每股收益 | 0.44 | 0.39 | 0.33 | 0.08 |
| (二)稀释每股收益 | 0.44 | 0.39 | 0.33 | 0.08 |
| 八、其他综合收益 | -7,452,241.92 | -2,431,348.64 | -2,431,348.64 | - |
| 归属于母公司股东的其他综合收益 | -7,452,241.92 | -2,431,348.64 | -2,431,348.64 | - |
| 九、综合收益总额 | 400,895,279.91 | 354,487,866.77 | 304,279,353.46 | 70,966,706.12 |
| 归属于母公司股东的综合收益总额 | 387,163,493.81 | 344,627,089.96 | 297,531,006.53 | 67,307,574.42 |
| 归属于少数股东的综合收益总额 | 13,731,786.1 | 9,860,776.81 | 6,748,346.93 | 3,659,131.7 |
| 公告日期 | 2025-03-22 | 2024-10-30 | 2024-08-22 | 2024-04-24 |
| 审计意见(境内) | 标准无保留意见 | | | |